KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash from Financing Activities: 2018-2025

Historic Cash from Financing Activities for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -$1.0 million.

  • Moderna's Cash from Financing Activities fell 109.09% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 118.00%. This contributed to the annual value of $56.0 million for FY2024, which is 104.07% up from last year.
  • Moderna's Cash from Financing Activities amounted to -$1.0 million in Q3 2025, which was down 111.11% from $9.0 million recorded in Q2 2025.
  • Moderna's Cash from Financing Activities' 5-year high stood at $34.0 million during Q2 2024, with a 5-year trough of -$1.3 billion in Q2 2022.
  • Its 3-year average for Cash from Financing Activities is -$119.0 million, with a median of -$1.0 million in 2025.
  • In the last 5 years, Moderna's Cash from Financing Activities slumped by 51,950.00% in 2022 and then soared by 118.97% in 2024.
  • Moderna's Cash from Financing Activities (Quarterly) stood at -$873.0 million in 2021, then soared by 49.83% to -$438.0 million in 2022, then soared by 75.11% to -$109.0 million in 2023, then soared by 97.25% to -$3.0 million in 2024, then tumbled by 109.09% to -$1.0 million in 2025.
  • Its last three reported values are -$1.0 million in Q3 2025, $9.0 million for Q2 2025, and $4.0 million during Q1 2025.